Literature DB >> 2514475

The relationship between uncomplicated schistosomiasis and hepatitis B infection.

M A Madwar1, M el Tahawy, G T Strickland.   

Abstract

Clinical and laboratory findings and hepatitis B virus (HBV) markers were compared in 105 patients with uncomplicated schistosomiasis mansoni, schistosomiasis haematobium, or both infections. 34 (32%) had HBs antigen (Ag); 51 (49%) had anti-HBs and/or anti-HBc; 20 (19%) had no markers for HBV. In comparison with the non-HBV-infected group, the group with HBsAg had more complaints of nausea and vomiting, and higher mean values for serum bilirubin and aspartate aminotransferase, and were less likely to complain of loose stools. In comparison with the non-HBV-infected group both groups having HBV markers were older, more likely to have received prior therapy (parenteral therapy in particular) for schistosomiasis, less likely to complain of blood in their stools, and more likely to have higher serum total proteins, albumin, globulin, and alanine aminotransferase. This study supports two mechanisms which could cause an association between HBV infection and schistosomiasis: (i) self-selection by patients with schistosomiasis seeking medical care for symptoms due to HBV infection and (ii) iatrogenic infection with HBV during parenteral treatment for schistosomiasis. It also suggests that much of the clinical morbidity ascribed to uncomplicated chronic schistosomiasis may be caused by a concomitant occult HBV infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514475     DOI: 10.1016/0035-9203(89)90657-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  11 in total

Review 1.  Curse of schistosomiasis on Egyptian liver.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

Review 2.  Tropical medicine.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

3.  Gastrointestinal complications of schistosomiasis.

Authors:  T W Schafer; B R Hale
Journal:  Curr Gastroenterol Rep       Date:  2001-08

Review 4.  Gastrointestinal manifestations of schistosomiasis.

Authors:  G T Strickland
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

5.  Hepatocellular carcinoma in Egypt: a single center study over a decade.

Authors:  Abdel-Rahman el-Zayadi; Hanaa M Badran; Eman M F Barakat; Mohy el-Deen Attia; Sherine Shawky; Mostafa K Mohamed; Osaima Selim; Ahmed Saeid
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

6.  High prevalence of hepatitis C in Egyptian patients with chronic liver disease.

Authors:  I A Waked; S M Saleh; M S Moustafa; A A Raouf; D L Thomas; G T Strickland
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

7.  Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance.

Authors:  J K Actor; M Shirai; M C Kullberg; R M Buller; A Sher; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

8.  Inhibition of hepatitis B virus replication during schistosoma mansoni infection in transgenic mice.

Authors:  H McClary; R Koch; F V Chisari; L G Guidotti
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

9.  The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani.

Authors:  Mohammed F Hassan; Yaobi Zhang; Christian R Engwerda; Paul M Kaye; Hannah Sharp; Quentin D Bickle
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

10.  Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.

Authors:  Amal Abdul-rasheed El-Moamly; Mohamed Aly El-Sweify; Rafiaa M Rashad; Esam M Abdalla; Mostafa M Ragheb; Mohamed M Awad
Journal:  Parasitol Res       Date:  2013-03-21       Impact factor: 2.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.